Patents are an important driver of prescription drug innovation. Recently, manufacturer practices under the current patent system have come under scrutiny for blocking or delaying the entry of generic or biosimilar drugs into the market. The development of novel therapies plays a critical role in treating, and in some cases eradicating, debilitating and costly diseases. However, the high cost of prescription drugs continues to challenge patients and the health care system. The sale of biosimilar and generic drugs offers a promising opportunity to promote prescription drug affordability through competition. During this webinar, panelists explored the relationship between patents, prices, and patient access.
- Priti Krishtel, J.D., Co-Founder and Co-Executive Director, I-MAK @pritikrishtel
- Genia Long, MPP, Senior Advisor, Analysis Group
- Ed Silverman, M.A., Pharmalot Columnist and Senior Writer, STAT @pharmalot
Join the conversation on Twitter using the hashtag #AllHealthLive
The Alliance for Health Policy gratefully acknowledges the support of the National Institute of Health Care Management (NIHCM) and the Association of Health Care Journalists (AHCJ) for this event.